Clik here to view.
Clinigen signs agreement with Nordic Pharma for aprotinin
BURTON-ON-TRENT, England Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an agreement with Nordic Pharma Ltd. (‘Nordic Pharma’) to manage the...
View ArticleClik here to view.
Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and...
TOKYO The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio, Inc.), a scientific leader in regenerative medicine for neurological disorders, hereby announces that Cell Therapy for Chronic Stroke,...
View ArticleClik here to view.
Analytics 4 Life®的医学顾问委员会新增全球心内科专家
北卡罗莱纳州研究三角园区和多伦多 (美国商业资讯) — Analytics 4 Life是一家数字健康公司，将人工智能的功能应用于制订可改善现有医护路径的解决方案，该公司今天宣布，其医学顾问委员会新增两位全球心内科和数字健康专家。葛均波医学博士是中华医学会心血管病学分会主任委员和中国心血管健康联盟主席。Sanjeev Bhavnani,...
View ArticleClik here to view.
Jupl Safety Watch Goes Retail
AUCKLAND, New Zealand & SYDNEY Jupl uses the Samsung Gear S3 watch in conjunction with its own cloud-based monitoring and analytics system. This, in collaboration with Spark and Cisco Jasper,...
View ArticleClik here to view.
GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler...
LONDON & BRISBANE, Calif. GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of a regulatory application to the Japanese Ministry of Health,...
View ArticleClik here to view.
Octapharma在 WFH 2018上分享新型皮下重组FVIII SubQ-8的有前景的临床前数据
瑞士拉亨 (美国商业资讯) — Octapharma今天宣布，SubQ-8临床前数据在英国格拉斯哥召开的世界血友病联盟(WFH) 2018年世界大会的一次研讨会上呈报。 SubQ-8目前正在开发中，是来自于人类细胞系的重组FVIII，用于皮下给药。SubQ-8的基础是Octapharma的人类细胞系衍生rFVIII产品simoctocog alpha结合 von...
View ArticleClik here to view.
Octapharma在世界血友病联盟2018年世界大会上呈报Nuwiq®造福血友病A患者的新数据
瑞士拉亨 (美国商业资讯) – Octapharma今天宣布，Nuwiq®造福血友病A患者的新数据在英国格拉斯哥召开的世界血友病联盟(WFH) 2018年世界大会的一次研讨会上呈报。Nuwiq® 是第四代人类细胞系衍生的重组FVIII (rFVIII)，获准用于预防和治疗所有年龄段血友病A患者的出血发作。此次研讨会名为“进一步满足临床需求：来自Nuwiq®▼（simoctocog...
View ArticleClik here to view.
China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir),...
FOSTER CITY, Calif. Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China Drug Administration (CDA) has approved Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of...
View ArticleClik here to view.
Clik here to view.
Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm®...
SAN JOSE, Calif. Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Link Health Group LTD (“Link Health”) to develop market, sell, and...
View ArticleClik here to view.
vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co....
HIGH POINT, N.C. vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to...
View ArticleClik here to view.
FORMA Therapeutics and HitGen Initiate Multiyear Research Collaboration
WATERTOWN, Mass. & CHENGDU, China FORMA Therapeutics and HitGen Ltd. today announced a multiyear research collaboration and license agreement to build and screen proprietary DNA-encoded...
View ArticleClik here to view.
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement...
SHANGHAI & ROTTERDAM, Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has licensed its patented H2L2 fully human antibody discovery platform to Celsius Therapeutics, a...
View ArticleClik here to view.
Samsung Bioepis Announces Results of Additional One-Year Follow-up Study on...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced additional one-year follow-up study results on SB3, a biosimilar candidate referencing Herceptin® 1 (trastuzumab). The data was made...
View ArticleClik here to view.
Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of...
View ArticleClik here to view.
タイヨウ・パシフィック・パートナーズ、そーせいグループ（4565）株式を 5％超取得
東京 （ビジネスワイヤ）– タイヨウ･パシフィック・パートナーズは本日、そーせいグループ株式会社（4565）の発行済株式総数の 5％超を取得し、実質調査ベースで第...
View ArticleClik here to view.
Taiyo Pacific Partners Becomes Major Shareholder in Sosei Group Corporation...
TOKYO Taiyo Pacific Partners announced today that it has accumulated in excess of 5% in Sosei Group Corporation (4565) to become Sosei’s second largest shareholder. The company (or “Sosei”) is an...
View ArticleClik here to view.
Nerviano Medical Sciences宣布与默克签署合作及授权协议，以发现某些抗癌靶点的小分子抑制剂
意大利内尔维亚诺 (美国商业资讯) — 意大利最大的制药研发机构、欧洲领先的专攻肿瘤领域的发现及开发一体化公司之一Nerviano Medical Sciences今天宣布，与领先的科技公司默克签署协议，合作发现面向抗癌药开发的小分子抑制剂。 根据协议条款，Nerviano Medical...
View ArticleClik here to view.
Clik here to view.
Pierre Fabre and Its Partner Array BioPharma Announce Additional Median...
CASTRES, France Pierre Fabre and its partner Array BioPharma Inc. today announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed median overall...
View Article